Baker McKenzie
We only have limited information for this firm. Consider the following firms which have provided more information:
Praised by clients for its ‘endless experience and care’, the team at Baker McKenzie displays deep bench strength across a wide variety of matters, including pharmacovigilance, product registration, pricing, reimbursement procedures, and the implementation of patient support programmes. Montserrat Llopart leads the team from Barcelona, utilising her longstanding regulatory expertise to advise on compliance audits, the drafting of codes of professional ethics, and clinical trial contracts. In Madrid, ‘excellent’ practice head Cecilia Pastor acts for healthcare companies in a host of matters, including corporate restructurings and global supply chains, while Ester Navas assists medical device and pharma companies with the regulatory aspects of their promotional activities, price discounting issues, and contractual matters involving third parties.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Baker has a multidisciplinary and diverse team that I can count on at any time for any issue. They know my business and my business model and they give me security and confidence. They work very well. The differentiating element that distinguishes them from the rest of the market is their hands-on approach. They bring together the best of local and international practices.’
‘Cecilia Pastor is excellent, one of the best lawyers I know. I wouldn't hesitate to recommend her. She has great analytical skills, market knowledge, practical vision and a lot of experience. She brings a lot of value.’
Abbreviated data is displayed for this firm.
Key clients
- Abbott
- AbbVie
Abbreviated data is displayed for this firm.
Work highlights
- Advising Medtronic plc on its plans to sell or spin off two large divisions, Patient Monitoring and Respiratory Interventions businesses.
- Assisted Ferrer Internacional in the drafting and negotiation of its license agreement with Asceneuron in which Ferrer obtained the exclusive worldwide rights to develop and commercialise ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Abbreviated data is displayed for this firm.